Amanote Research
Register
Sign In
Pgi22 - Cost-Effectiveness of Vedolizumab Versus Ustekinumab in United Kingdom Crohn's Disease Patients Who Previously Failed TNF Inhibitor Therapy
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.864
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
M. Wilson
A. Lucas
Publisher
Elsevier BV
Related search
Psy114 - Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy in Patients With Crohn’s Disease in the United Kingdom (Uk)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Gastroenterology
Hepatology
Gastroenterology
Treatment of Complicated Crohn's Disease With Vedolizumab
Gastroenterologie a Hepatologie
Hepatology
Gastroenterology
Letter: Biologics Treatment in Crohn's Disease and Risk of Bowel Resection-What About the Patients Who Stop Anti-TNF Therapy? Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
PUK10 Cost-Effectiveness Analysis of Solifenacin Versus Oxybutynin Immediate-Release in the Treatment of Patients With Overactive Bladder in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Review Article: Predictors of Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
